Skip to main content
Top

Open Access 15-04-2024 | Neuroendocrine Tumor | Rapid Communication

When rare diseases crisscross within the same patient: von Hippel-Lindau and type 1 gastric neuroendocrine tumor

Authors: Krystallenia I. Alexandraki, Ariadni Spyroglou, Paraskevi Xekouki, Konstantinos I. Bramis, Georgios Kyriakopoulos, Konstantinos Barkas, Ioannis S. Papanikolaou, George Mastorakos, Manousos Konstadoulakis

Published in: Hormones

Login to get access

Abstract

Von-Hippel-Lindau (VHL) is a genetic multisystem disorder characterized by visceral cysts and benign and malignant tumors in various organs. Herein, we present the case of a 23-year-old woman with VHL presenting with multiple gastric neuroendocrine neoplasms (gNENs) type 1 in the context of chronic autoimmune gastritis (CAG). Although gNENs are not acknowledged as a typical entity in VHL patients, in the present case, gNENs were composed of neoplastic cells with clear cytoplasm usually seen in tumors related to VHL disease. We additionally performed a literature review on the presence of neuroendocrine clear cell tumors and report on further cases of clear cell NENs. The present case illustrates that clear-cell transformation in gNENs may be due to the dual genetic background of the patient; the real oncogenic stimulus may be more closely related to CAG than to VHL disease accompanied by an interplay between neoplastic and autoimmune processes. Therefore, close monitoring of patients with clear cell NENs appears to be important before excluding VHL disease, even in the context of phenotypically unrelated diseases.
Literature
1.
go back to reference Binderup MLM (2018) von Hippel-Lindau disease: Diagnosis and factors influencing disease outcome. Dan Med J 65:B5461 Binderup MLM (2018) von Hippel-Lindau disease: Diagnosis and factors influencing disease outcome. Dan Med J 65:B5461
2.
go back to reference Binderup ML, Smerdel M, Borgwadt L, Beck Nielsen SS, Madsen MG et al (2022) von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance. Eur J Med Genet 65:104538CrossRef Binderup ML, Smerdel M, Borgwadt L, Beck Nielsen SS, Madsen MG et al (2022) von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance. Eur J Med Genet 65:104538CrossRef
4.
go back to reference Dasari A, Shen C, Halperin D, Zhao B, Zhou S et al (2017) Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 3:1335–1342CrossRefPubMedPubMedCentral Dasari A, Shen C, Halperin D, Zhao B, Zhou S et al (2017) Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 3:1335–1342CrossRefPubMedPubMedCentral
5.
go back to reference Grozinsky-Glasberg S, Alexandraki KI, Angelousi A, Chatzellis E, Sougioultzis S et al (2018) Gastric Carcinoids. Endocrinol Metab Clin North Am 47:645–660CrossRefPubMed Grozinsky-Glasberg S, Alexandraki KI, Angelousi A, Chatzellis E, Sougioultzis S et al (2018) Gastric Carcinoids. Endocrinol Metab Clin North Am 47:645–660CrossRefPubMed
6.
go back to reference Kaltsas G, Grozinsky-Glasberg S, Alexandraki KI, Thomas D, Tsolakis AV et al (2014) Current concepts in the diagnosis and management of type 1 gastric neuroendocrine neoplasms. Clin Endocrinol (Oxf) 81:157–168CrossRefPubMed Kaltsas G, Grozinsky-Glasberg S, Alexandraki KI, Thomas D, Tsolakis AV et al (2014) Current concepts in the diagnosis and management of type 1 gastric neuroendocrine neoplasms. Clin Endocrinol (Oxf) 81:157–168CrossRefPubMed
7.
go back to reference Alexandraki KI, Nikolaou A, Thomas D, Syriou V, Korkolopoulou P et al (2014) Are patients with autoimmune thyroid disease and autoimmune gastritis at risk of gastric neuroendocrine neoplasms type 1? Clin Endocrinol (Oxf) 80:685–690CrossRefPubMed Alexandraki KI, Nikolaou A, Thomas D, Syriou V, Korkolopoulou P et al (2014) Are patients with autoimmune thyroid disease and autoimmune gastritis at risk of gastric neuroendocrine neoplasms type 1? Clin Endocrinol (Oxf) 80:685–690CrossRefPubMed
8.
go back to reference Daskalakis K, Tsoli M, Karapanagioti A, Chrysochoou M, Thomas D et al (2019) Recurrence and metastatic potential in Type 1 gastric neuroendocrine neoplasms. Clin Endocrinol (Oxf) 91:534–543CrossRefPubMed Daskalakis K, Tsoli M, Karapanagioti A, Chrysochoou M, Thomas D et al (2019) Recurrence and metastatic potential in Type 1 gastric neuroendocrine neoplasms. Clin Endocrinol (Oxf) 91:534–543CrossRefPubMed
9.
go back to reference Panzuto F, Ramage J, Pritchard DM, van Velthuysen MF, Schrader J et al (2023) European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1–G3. J Neuroendocrinol 35:e13306CrossRefPubMed Panzuto F, Ramage J, Pritchard DM, van Velthuysen MF, Schrader J et al (2023) European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1–G3. J Neuroendocrinol 35:e13306CrossRefPubMed
10.
go back to reference Rossi RE, Invernizzi P, Mazzaferro V, Massironi S (2020) Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids: A systematic review and meta-analysis. United European Gastroenterol J 8:140–147CrossRefPubMed Rossi RE, Invernizzi P, Mazzaferro V, Massironi S (2020) Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids: A systematic review and meta-analysis. United European Gastroenterol J 8:140–147CrossRefPubMed
11.
go back to reference Kawaguchi K, Yashima K, Ikebuchi Y, Yoshida A, Kuwamoto S et al (2022) The First Case of Gastric Neuroendocrine Tumors Induced by a Proton Pump Inhibitor in von Hippel-Lindau Disease. Intern Med 61:2587–2592CrossRefPubMedPubMedCentral Kawaguchi K, Yashima K, Ikebuchi Y, Yoshida A, Kuwamoto S et al (2022) The First Case of Gastric Neuroendocrine Tumors Induced by a Proton Pump Inhibitor in von Hippel-Lindau Disease. Intern Med 61:2587–2592CrossRefPubMedPubMedCentral
12.
go back to reference Woo CG, Choi SY, Kwak JJ, Chin S, Kim HK (2017) Clear cell neuroendocrine tumor of the pancreas in von Hippel-Lindau disease: a case report and literature review. Neuro Endocrinol Lett 38:83–86PubMed Woo CG, Choi SY, Kwak JJ, Chin S, Kim HK (2017) Clear cell neuroendocrine tumor of the pancreas in von Hippel-Lindau disease: a case report and literature review. Neuro Endocrinol Lett 38:83–86PubMed
13.
go back to reference Hoang MP, Hruban RH, Albores-Saavedra J (2001) Clear cell endocrine pancreatic tumor mimicking renal cell carcinoma: a distinctive neoplasm of von Hippel-Lindau disease. Am J Surg Pathol 25:602–609CrossRefPubMed Hoang MP, Hruban RH, Albores-Saavedra J (2001) Clear cell endocrine pancreatic tumor mimicking renal cell carcinoma: a distinctive neoplasm of von Hippel-Lindau disease. Am J Surg Pathol 25:602–609CrossRefPubMed
14.
go back to reference Sinkre PA, Murakata L, Rabin L, Hoang MP, Albores-Saavedra J (2001) Clear cell carcinoid tumor of the gallbladder: another distinctive manifestation of von Hippel-Lindau disease. Am J Surg Pathol 25:1334–1339CrossRefPubMed Sinkre PA, Murakata L, Rabin L, Hoang MP, Albores-Saavedra J (2001) Clear cell carcinoid tumor of the gallbladder: another distinctive manifestation of von Hippel-Lindau disease. Am J Surg Pathol 25:1334–1339CrossRefPubMed
15.
go back to reference Gucer H, Szentgyorgyi E, Ezzat S, Asa SL, Mete O (2013) Inhibin-expressing clear cell neuroendocrine tumor of the ampulla: an unusual presentation of von Hippel-Lindau disease. Virchows Arch 463:593–597CrossRefPubMed Gucer H, Szentgyorgyi E, Ezzat S, Asa SL, Mete O (2013) Inhibin-expressing clear cell neuroendocrine tumor of the ampulla: an unusual presentation of von Hippel-Lindau disease. Virchows Arch 463:593–597CrossRefPubMed
Metadata
Title
When rare diseases crisscross within the same patient: von Hippel-Lindau and type 1 gastric neuroendocrine tumor
Authors
Krystallenia I. Alexandraki
Ariadni Spyroglou
Paraskevi Xekouki
Konstantinos I. Bramis
Georgios Kyriakopoulos
Konstantinos Barkas
Ioannis S. Papanikolaou
George Mastorakos
Manousos Konstadoulakis
Publication date
15-04-2024
Publisher
Springer International Publishing
Published in
Hormones
Print ISSN: 1109-3099
Electronic ISSN: 2520-8721
DOI
https://doi.org/10.1007/s42000-024-00556-9
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.